Français
ItalianoBond Eli Lilly & Company 2.75% ( US532457BH00 ) in USD
| Issuer | Eli Lilly & Company |
| Market price | 99.619 % ▲ |
| Country |  United States
|
| ISIN code |
 US532457BH00 ( in USD )
|
| Interest rate | 2.75% per year ( payment 2 times a year) |
| Maturity | 01/06/2025 - Bond has expired |
|
Prospectus brochure in PDF format is unavailable at this time We will provide it as soon as possible |
|
| Minimal amount | 2 000 USD |
| Total amount | 800 000 000 USD |
| Cusip | 532457BH0 |
| Standard & Poor's ( S&P ) rating | A+ ( Upper medium grade - Investment-grade ) |
| Moody's rating | Aa3 ( High grade - Investment-grade ) |
| Detailed description |
Eli Lilly and Company is a global pharmaceutical company specializing in the research, development, manufacturing, and marketing of pharmaceutical products and biologicals. Eli Lilly and Company, a renowned global pharmaceutical giant headquartered in the United States, frequently accesses capital markets to fund its extensive research and development initiatives and operational requirements, as exemplified by a recently matured and fully repaid bond identified by ISIN US532457BH00 and CUSIP 532457BH0; this debt instrument, issued in the United States, carried a fixed interest rate of 2.75% with a semiannual payment frequency, was denominated in USD, and was available for purchase in a minimum lot size of $2,000; the bond, which matured on June 1, 2025, and has since been fully repaid to investors, was observed trading at approximately 99.619% of its par value prior to its redemption; its strong investment-grade status, reflecting Eli Lilly's robust financial health and commitment to its debt obligations, was underscored by a formidable A+ rating from Standard & Poor's and an Aa3 rating from Moody's. |